Exelixis, Inc. (BIT:1EXEL)

Italy flag Italy · Delayed Price · Currency is EUR
39.13
0.00 (0.00%)
Last updated: Jul 15, 2025
Market Cap10.33B
Revenue (ttm)2.13B
Net Income (ttm)595.43M
Shares Outn/a
EPS (ttm)2.04
PE Ratio17.35
Forward PE15.80
Dividendn/a
Ex-Dividend Daten/a
Volumen/a
Average Volume79
Open39.13
Previous Close39.13
Day's Range39.13 - 39.13
52-Week Range34.18 - 42.61
Betan/a
RSI52.30
Earnings DateAug 5, 2025

About Exelixis

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF recep... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 1994
Employees 1,147
Stock Exchange Borsa Italiana
Ticker Symbol 1EXEL
Full Company Profile

Financial Performance

In 2024, Exelixis's revenue was $2.17 billion, an increase of 18.49% compared to the previous year's $1.83 billion. Earnings were $521.27 million, an increase of 150.89%.

Financial numbers in USD Financial Statements

News

There is no news available yet.